SHH and medulloblastoma: The SJYC07 trial, a multicenter, phase 2 study, demonstrated that risk-adapted chemotherapy-alone regimens can achieve favorable long-term survival in infants and young children with desmoplastic/nodular or Sonic Hedgehog (SHH)-activated medulloblastoma without metastasis, while sparing them from the neurocognitive sequelae of craniospinal irradiation [20].